Silencing YY1 Alleviates Ox-LDL-Induced Inflammation and Lipid Accumulation in Macrophages through Regulation of PCSK9/ LDLR Signaling
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The formation of macrophage foam cells stimulated by oxidized low-density lipoprotein (ox-LDL) is deemed an important cause of atherosclerosis. Transcription factor Yin Yang 1 (YY1), which is a universally expressed multifunctional protein, is closely related to cell metabolism disorders such as lipid metabolism, sugar metabolism, and bile acid metabolism. However, whether YY1 is involved in macrophage inflammation and lipid accumulation still remains unknown. After mouse macrophage cell line RAW264.7 cells were induced by ox-LDL, YY1 and proprotein convertase subtilisin/kexin type 9 (PCSK9) expressions were found to be increased while low-density lipoprotein receptor (LDLR) expression was lowly expressed. Subsequently, through reverse transcription‐quantitative polymerase chain reaction (RT-qPCR), Western blot analysis, Oil Red O staining and cholesterol quantification, it turned out that silencing of YY1 attenuated the inflammatory response and lipid accumulation in RAW264.7 cells caused by ox-LDL. Moreover, results from the JASPAR database, chromatin immunoprecipitation (ChIP) assay, luciferase reporter assay and Western blot analysis suggested that YY1 activated PCSK9 by binding to PCSK9 promoter and modulated the expression of LDLR in the downstream of PCSK9. In addition, the results of functional experiments demonstrated that the inhibitory effects of YY1 interference on ox-LDL-mediated macrophage inflammation and lipid accumulation were reversed by PCSK9 overexpression. To sum up, YY1 depletion inhibited its activation of PCSK9, thereby reducing cellular inflammatory response, cholesterol homeostasis imbalance, and lipid accumulation caused by ox-LDL.
Abstract
The formation of macrophage foam cells stimulated by oxidized low-density lipoprotein (ox-LDL) is deemed an important cause of atherosclerosis. Transcription factor Yin Yang 1 (YY1), which is a universally expressed multifunctional protein, is closely related to cell metabolism disorders such as lipid metabolism, sugar metabolism, and bile acid metabolism. However, whether YY1 is involved in macrophage inflammation and lipid accumulation still remains unknown. After mouse macrophage cell line RAW264.7 cells were induced by ox-LDL, YY1 and proprotein convertase subtilisin/kexin type 9 (PCSK9) expressions were found to be increased while low-density lipoprotein receptor (LDLR) expression was lowly expressed. Subsequently, through reverse transcription‐quantitative polymerase chain reaction (RT-qPCR), Western blot analysis, Oil Red O staining and cholesterol quantification, it turned out that silencing of YY1 attenuated the inflammatory response and lipid accumulation in RAW264.7 cells caused by ox-LDL. Moreover, results from the JASPAR database, chromatin immunoprecipitation (ChIP) assay, luciferase reporter assay and Western blot analysis suggested that YY1 activated PCSK9 by binding to PCSK9 promoter and modulated the expression of LDLR in the downstream of PCSK9. In addition, the results of functional experiments demonstrated that the inhibitory effects of YY1 interference on ox-LDL-mediated macrophage inflammation and lipid accumulation were reversed by PCSK9 overexpression. To sum up, YY1 depletion inhibited its activation of PCSK9, thereby reducing cellular inflammatory response, cholesterol homeostasis imbalance, and lipid accumulation caused by ox-LDL.
참고문헌 (37)
- Khatana C, "Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis", Oxid. Med. Cell. Longev, 2020, pp.5245308~ (2020)
- Chistiakov DA, "Mechanisms of foam cell formation in atherosclerosis", J. Mol. Med, 95, pp.1153~1165 (2017)
- Kattoor AJ, "Role of Ox-LDL and LOX-1 in Atherogenesis", Curr. Med. Chem, 26, pp.1693~1700 (2019)
- Pirillo A, "LOX-1, OxLDL, and atherosclerosis", Mediators Inflamm, 2013, pp.152786~ (2013)
- Ericsson J, "YY1 is a negative regulator of transcription of three sterol regulatory element-binding protein-responsive genes", J. Biol. Chem, 274, pp.14508~14513 (1999)
- Zhang M, "Multifunctional YY1 in liver diseases", Semin. Liver Dis, 37, pp.363~376 (2017)
- Pan G, "Multifaceted regulation of hepatic lipid metabolism by YY1", Life Sci. Alliance, 4, pp.e202000928~ (2021)
- Li Y, "Yin Yang 1 facilitates hepatocellular carcinoma cell lipid metabolism and tumor progression by inhibiting PGC-1β-induced fatty acid oxidation", Theranostics, 9, pp.7599~7615 (2019)
- Zolova OE, "YY1 negatively regulates mouse myelin proteolipid protein(Plp1)gene expression in oligodendroglial cells", ASN Neuro, 3, pp.e00067~ (2011)
- Zhang XC, "YY1 promotes IL-6 expression in LPS-stimulated BV2microglial cells by interacting with p65 to promote transcriptional activation of IL-6", Biochem. Biophys. Res. Commun, 502, pp.269~275 (2018)
- Jian D, "Ox-LDL increases microRNA-29a transcription through upregulating YY1 and STAT1 in macrophages", Cell Biol. Int, 41, pp.1001~1011 (2017)
- Ummarino D, "Dyslipidaemia : anti-PCSK9 vaccines to halt atherosclerosis", Nat. Rev. Cardiol, 14, pp.442~443 (2017)
- Shapiro MD, "PCSK9 : from basic science discoveries to clinical trials", Circ. Res, 122, pp.1420~1438 (2018)
- Yurtseven E, "An update on the role of PCSK9 in atherosclerosis", J. Atheroscler. Thromb, 27, pp.909~918 (2020)
- Momtazi-Borojeni AA, "Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis", BMC Med, 17, pp.223~ (2019)
- Ricci C, "PCSK9 induces a pro-inflammatory response in macrophages", Sci. Rep, 8, pp.2267~ (2018)
- Chan JC, "A proprotein convertase subtilisin", kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates, 2009, pp.106, 9820~9825
- Maxwell KN, "Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment", Proc. Natl. Acad. Sci. USA, 102, pp.2069~2074 (2005)
- Zhou S, "miR-21", PTEN pathway mediates the cardioprotection of geniposide against oxidized low-density lipoprotein-induced endothelial injury via suppressing oxidative stress and inflammatory response, 2020, pp.45, 1305~1316
- Tsimikas S, "Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression", J. Am. College Cardiol, 58, pp.1715~1727 (2011)
- Gong M, "STAT6 upregulation promotes M2 macrophage polarization to suppress atherosclerosis", Med. Sci. Monitor Basic Res, 23, pp.240~249 (2017)
- Solanki A, "Evolving targets for the treatment of atherosclerosis", Pharmacol. Ther, 187, pp.1~12 (2018)
- Ding Z, "PCSK9 and inflammation : role of shear stress, pro-inflammatory cytokines, and LOX-1", Cardiovasc. Res, 116, pp.908~915 (2020)
- Fu W, "17β-Estradiol inhibits PCSK9-mediated LDLR degradation through GPER", PLC activation in HepG2 cells, 2019, pp.10, 930~
- Cui CJ, "Beneficial impact of epigallocatechingallate on LDL-C through PCSK9", LDLR pathway by blocking HNF1α and activating FoxO3a, 2020, pp.18, 195~
- Yin R, "MicroRNA-155 promotes the ox-LDL-induced activation of NLRP3inflammasomes via the ERK1", 2 pathway in THP-1 macrophages and aggravates atherosclerosis in ApoE-, Ann. Palliat. Med, pp.2019, 8[DOI]
- Ding Z, "NLRP3 inflammasome via IL-1β regulates PCSK9 secretion", Theranostics, 10, pp.7100~7110 (2020)
- Camell CD, "Inflammasome-driven catecholamine catabolism in macrophages blunts lipolysis during ageing", Nature, 550, pp.119~123 (2017)
- Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", New Eng. J. Med, 376, pp.1713~1722 (2017)
- Bernelot Moens SJ, "PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia", Eur. Heart J, 38, pp.1584~1593 (2017)
- Giunzioni I, "Local effects of human PCSK9 on the atherosclerotic lesion", J. Pathol, 238, pp.52~62 (2016)
- Li J, "Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis", Mol. Med. Rep, 16, pp.1817~1827 (2017)
- Li S, "Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease", Atherosclerosis, 234, pp.441~445 (2014)
- Li S, "PCSK9 : a key factor modulating atherosclerosis", J. Atheroscler. Thromb, 22, pp.221~230 (2015)
- Tang ZH, "PCSK9 : a novel inflammation modulator in atherosclerosis?", J. Cell Physiol, 234, pp.2345~2355 (2019)
- Keith R. Walley, "PCSK9 is a critical regulator of the innate immune response and septic shock outcome", Science Translational Medicine, 6(258) (2014), American Association for the Advancement of Science (AAAS)[DOI]
- Ding Z, "Cross-talk between LOX-1 and PCSK9 in vascular tissues", Cardiovasc. Res, 107, pp.556~567 (2015)